//
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
Mechanical circulatory support devices in advanced heart failure: 2020 and beyond
Readmission and Mortality After Hospitalization for Myocardial Infarction and Heart Failure
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
Dilated cardiomyopathy: so many cardiomyopathies!
Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions
Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5)